Completed
Intro
Class Central Classrooms beta
YouTube playlists curated by Class Central.
Classroom Contents
PARP Inhibitors in Ovarian Cancer Treatment - Webinar - Ambry Genetics
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Disclosures
- 3 OUTLINE
- 4 GOALS LEARNING OBJECTIVES
- 5 Cancer Probability for Females at Birth - USA
- 6 Frequency of Symptoms of Ovarian Cancer in Women Presenting to Primary Care Clinics
- 7 EPITHELIAL OVARIAN CANCER SIGNS
- 8 OVARIAN CANCER CLASSIFICATION
- 9 Epithelial Ovarian Cancer Cont... Five main histologic subtypes
- 10 Regulatory Pathways
- 11 Mucinous Carcinoma
- 12 Standard of Care
- 13 Chemotherapy Recurrent Disease Platinum Sensitive
- 14 Conventional Chemotherapy Side Effects
- 15 Cost Comparison Among Ovarian Cancer Treatments
- 16 Hereditary Susceptibility to
- 17 Clinical manifestation of hereditary ovarian cancer
- 18 LIFETIME RISK ESTIMATED IN BRCA1 & BRCA2 CARRIERS
- 19 BRCA1-RELATED OVARIAN CANCER
- 20 Hereditary breast and ovarian cancer syndrome (HBOC)
- 21 Targeted Therapies
- 22 Poly(ADP-Ribose) Polymerase (PARP) inhibition in ovarian cancer
- 23 PARP Inhibitors: Mechanism of Action
- 24 PARP Family
- 25 PARP Inhibitors Background
- 26 High Grade Serous Cancers (HGSC) & BRCA mutations
- 27 Phase I trial: Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
- 28 Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
- 29 PARP Inhibitors: Properties & Side Effects
- 30 Olaparib Clinical Trials
- 31 Ovarian cancer trials PARP 1 & 2 Inhibitors
- 32 Targeting Angiogenesis: VEGF
- 33 VEGF: Tyrosine kinase Inhibitor
- 34 Randomized phase II trial: Olaparib with Cediranib vs Olaparib alone in recurrent platinum sensitive
- 35 PARP Inhibitor Side effect Profile
- 36 In Summary
- 37 Targeting Therapies: Summary
